“…excellent legal work and value…”

Sean H. Mallean
President & CEO
Axeus, Inc

Johnson Fistel is currently investigating a number of publicly traded companies for allegedly violating state and federal laws, some of which are already named as a defendant in a securities fraud class action.

Pending Class Actions

For more information about existing securities fraud class actions, including upcoming important deadlines, please click here.

Investigations

For more information about ongoing investigations, please click on the name of the company below.

Sonder Holdings Inc.

Sonder Holdings Alert: Class Action Investigation Following Delayed Release of SOND Financial Information, Contact Johnson Fistel, LLP Shareholder rights law firm Johnson Fistel, LLP is investigating whether Sonder Holdings Inc. (“Sonder” or the “Company”) (NASDAQ: SOND), or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased Sonder securities? If you bought securities and suffered significant losses on your investment, join our investigation now: Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471. There is no cost or obligation to you. What is Johnson Fistel investigating? On March 15, 2024, Sonder announced it “recently identified accounting errors related to the valuation and impairment of operating lease right of use assets and related items for the fiscal years 2022

Ventyx Biosciences, Inc.

VTYX NEWS: Johnson Fistel Encourages Ventyx Biosciences Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX). The class action is on behalf of shareholders who purchased or otherwise Acquired: (a) Ventyx common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about October 21, 2021 (the “IPO” or “Offering”); and/or (b) Ventyx securities between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”).. Investors are hereby notified that they have until April 30, 2024, to move the Court to serve as lead plaintiff in this action. The complaint alleges that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material

Chegg, Inc.

Chegg Long-Term Shareholder Announcement: Johnson Fistel, LLP Encourages Investors to Submit Their Information Below Johnson Fistel, LLP is investigating potential claims on behalf of Chegg, Inc. (NYSE: CHGG) against certain of its officers and directors to hold them responsible for damages they allegedly caused the company to suffer. If you have continuously owned Chegg, Inc. shares since before November 1, 2021, you have certain legal rights as a shareholder.  If you want to learn more, please read below or submit your information below: Recently a class action lawsuit was filed against Chegg seeking damages, but only for those who acquired stock between May 5, 2020 to November 1, 2021 (the “Class Period”). If you purchased shares before the Class Period, you will not be able to participate in any recovery obtained in the class action, but you may be able to participate in a separate action seeking to hold the officers and directors who

Methode Electronics, Inc.

Legal Alert: Johnson Fistel has Commenced a Class Action Investigation Following Significant News Shareholder rights law firm Johnson Fistel, LLP is investigating whether Methode Electronics, Inc. (“Methode” or the “Company”) (NYSE: MEI) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased Methode securities? If you bought securities and suffered significant losses on your investment, join our investigation now: Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471 There is no cost or obligation to you. What is Johnson Fistel investigating? On July 14, 2023, Methode announced that its Chief Operating Officer, Joseph Khoury, had been placed on leave and that his “powers, authority and duties . . . were suspended.” Then, on December

Akero Therapeutics, Inc.

Akero Therapeutics Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of Akero Therapeutics Shareholders Shareholder rights law firm Johnson Fistel, LLP is investigating whether Akero Therapeutics, Inc. (“Akero” or “the Company”) (NASDAQ: AKRO) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased Akero securities? If you purchased securities and suffered significant losses on your investment, join our investigation now: Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471 There is no cost or obligation to you. What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Class Action: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). The class action is on behalf of shareholders who purchased or otherwise acquired securities between November 11, 2022 to November 8, 2023, both dates inclusive (the “Class Period”). Investors are hereby notified that they have until April 9, 2024, to move the Court to serve as lead plaintiff in this action. The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) defendants had overstated RELYVRIO’s (a dual UPRBax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol, for the treatment of ALS in adults in the U.S.) commercial prospects; (ii) patients were discontinuing treatment with RELYVRIO after six months;

AirSculpt Technologies

AIRS Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of AirSculpt Shareholders Shareholder rights law firm Johnson Fistel, LLP is investigating whether AirSculpt Technologies (NASDAQ: AIRS) (“AirSculpt” or the “Company”) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased AirSculpt securities? If you purchased securities and suffered significant losses on your investment, join our investigation now: Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471 There is no cost or obligation to you. What is Johnson Fistel investigating? On February 24, 2024, Fuzzy Panda Research issued a report titled “AirSculpt – A “Liposuction Chop-Shop’ Cover-up of Patient’s Death, Sanctioned/Under-Certified Doctors, Fabricated Reviews, and Photoshopped Images Exposed.” The report states among

Fluence Energy, Inc.

FLNC NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Fluence Energy Shareholders Shareholder rights law firm Johnson Fistel, LLP is investigating whether Fluence Energy, Inc. (NASDAQ: FLNC) (the “Company”) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased Fluence Energy securities? If you purchased securities and suffered significant losses on your investment, join our investigation now: Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471 There is no cost or obligation to you. What is Johnson Fistel investigating? On February 22, 2024, Blue Orca Capital issued a report outlining the firm’s concerns with Fluence Energy. The report states Siemens, the U.S. affiliate of the Company’s largest shareholder and corporate parent, has

Amplitude, Inc.

AMPL NEWS: Johnson Fistel Encourages Amplitude Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Amplitude, Inc. (NASDAQ: AMPL). The class action is on behalf of shareholders who purchased or otherwise acquired securities between September 21, 2021 and February 16, 2022, both dates inclusive (the “Class Period”). Investors are hereby notified that they have until April 15, 2024, to move the Court to serve as lead plaintiff in this action. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Amplitude’s land-and-expand strategy was years away from significantly accelerating revenues among its newer client cohorts; (2) the rapid acceleration in Amplitude’s second quarter 2021 results resulted from the ephemeral effects of the COVID-19 pandemic which had not continued by the start of the Class Period,

LuxUrban Hotels Inc.

LUXH NEWS: Johnson Fistel Encourages LuxUrban Hotels Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of LuxUrban Hotels Inc. (NASDAQ: LUXH). The class action is on behalf of shareholders who purchased or otherwise acquired securities between November 8, 2023 and February 2, 2024. Investors are hereby notified that they have until April 12, 2024, to move the Court to serve as lead plaintiff in this action. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) LuxUrban had not signed a lease with the Royalton Hotel, a four star hotel located in New York; (2) as a result, LuxUrban’s total reported units was overstated; (3) LuxUrban faced multiple lawsuits for unpaid rent; and (4) as a result of the foregoing, defendants’ positive statements about LuxUrban’s

Evolv Technologies Holdings, Inc.

EVLV NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Evolv Technologies Shareholders Johnson Fistel, is investigating potential securities claims against Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) on behalf of stockholders. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471 There is no cost or obligation to you.  On February 19, 2024, Evolv Technology disclosed that the SEC was initiating an investigation into the company described as a confidential “non-public, fact finding inquiry.” Following this news, the company’s stock price dropped more than 20% on February 20, 2024. What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances,

HireRight Holdings

SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of HireRight; Are Shareholders Getting a Fair Deal? Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of HireRight Holdings (NYSE: HRT) breached their fiduciary duties in connection with the proposed sale of the Company to the investment funds affiliated with General Atlantic and Stone Point Capital. On February 16, 2024, HireRight announced that it had entered a deal to merge with General Atlantic and Stone Point Capital. Under the terms of the deal, HireRight shareholders will receive $14.35 per share in an all-cash offer. The investigation concerns whether the HireRight board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for HireRight shares of common stock. Nationally recognized, Johnson Fistel is investigating whether the proposed deal

The Beauty Health Company

Long-Term Shareholders of The Beauty Health Company Alert: Johnson Fistel, LLP Encourages Investors to Reach Out to the Firm Johnson Fistel, LLP is investigating potential claims on behalf of The Beauty Health Company (NASDAQ: SKIN against certain of its officers and directors. If you are a current, long-term shareholder of The Beauty Health Company holding shares before 2011, you may have standing to hold the company harmless from the alleged harm caused by the Company’s officers and directors by making them personally responsible. You may also be able to assist in reforming the Company’s corporate governance to prevent future wrongdoing. You can submit your information below in a browser to join this action: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Syndeo 1.0 and 2.0 devices had issues leading to “frequent treatment interruptions;” (2) as a result,

Temenos AG

TMSNY NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Temenos Shareholders Shareholder rights law firm Johnson Fistel, LLP is investigating whether Temenos AG (“Temenos” or the “Company”) (Other OTC: TMSNY) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased Temenos securities? If you purchased securities and suffered significant losses on your investment, join our investigation now: Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471 There is no cost or obligation to you. What is Johnson Fistel investigating? On February 15, 2024, Hindenburg Research issued a report entitled “Temenos: Major Accounting Irregularities, Failed Products And An Illusive Turnaround.” Hindenburg stated, “Our 4-month investigation into Temenos, involving interviews with 25 former employees,

Kaman Corporation

SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Kaman Corporation; Is $46 a Fair Price? Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Kaman Corporation (NYSE: KAMN) (“Kaman or “the Company”) breached their fiduciary duties in connection with the proposed sale of the Company to Arcline Investment Management, L.P. (“Arcline”). Upon completion of the transaction, Kaman will become a privately held company. On January 19, 2024, Kaman announced that it had entered into a deal to merge with Arcline. Under the terms of the deal, Kaman shareholders will receive $46.00 per share in an all-cash offer. The investigation concerns whether the Kaman board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Kaman shares of common stock. Nationally recognized, Johnson Fistel

Brooge Energy Limited

BROG NEWS: Johnson Fistel Encourages Brooge Energy Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline Johnson Fistel, LLP notifies investors of Brooge Energy Limited (NASDAQ: BROG) that a securities class action lawsuit has been filed. The complaint alleges Brooge made misleading statements and failed to disclose that it: (1) overstated revenues because it never received any revenues from related party A1 Brooge International Advisory LLC (“BIA”), as well as from another fake customer (“Customer A”); (2) engaged in a complex pattern of payments with BIA to create the illusion of revenues from BIA and another customer who had no knowledge of the fraud; (3) intentionally lied to its auditors and the SEC about its fraudulent activities; and (4) lacked internal controls. The lawsuit seeks to recover losses on behalf of investors who acquired securities between November 25, 2019 and December 21, 2023. Investors have until April 5, 2024,

iRhythm Technologies, Inc.

IRTC NEWS: Johnson Fistel Encourages iRhythm Technologies Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline Johnson Fistel, LLP notifies investors of iRhythm Technologies, Inc. (NASDAQ: IRTC) that a securities class action lawsuit has been filed. According to the lawsuit, defendants falsely represented to investors that one of iRhythm’s main products, the Zio AT monitor, was a real-time heart monitor intended for high-risk patients. Specifically, defendants repeatedly touted the potential growth for the Zio AT as an innovative product that had only just begun to penetrate the market for real-time monitoring, which investors looked upon favorably given the premium selling price associated with devices approved for high-risk patients. As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the class period. The lawsuit seeks to recover losses on behalf of investors who acquired securities between January 11, 2022 and May 30,

Hut 8 Corp.

HUT NEWS: Johnson Fistel Encourages Hut 8 Corp. Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline Johnson Fistel, LLP notifies investors of Hut 8 Corp. (NASDAQ: HUT) that a securities class action lawsuit has been filed. The Hut 8 class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) one of USBTC’s largest shareholders is an undisclosed related party; (ii) USBTC’s core asset has historically failed to provide energy and high-speed internet; and (iii) the profitability of certain USBTC assets were overstated. The lawsuit seeks to recover losses on behalf of investors who acquired securities between November 9, 2023 and January 18, 2024. Investors have until April 8, 2024, to apply to the Court to be appointed as lead plaintiff in the lawsuit. What can Investors Do: Shareholders who incurred losses during the class period, have until April 8,

Soho House & Co Inc.

Johnson Fistel Announces Investigation of Soho House (SHCO) for Potential Securities Law Violations Johnson Fistel, LLP is investigating Soho House & Co Inc. (“Soho House” or “the Company”) (NYSE: SHCO) for potential securities law violations. Shareholders who have incurred losses on their investment in the company are encouraged to contact the firm to learn about potentially recovering their losses. What is Johnson Fistel investigating? On February 7, 2024, GlassHouse Research issued a report stating the concerns the firm has with the company’s operations. The report goes on to say the company is experiencing a broken business model as well as questionable accounting practices. GlassHouse states that the grievances it has with the company’s accounting include artificially aiding earnings metrics and a “lack of an opinion on internal controls by its auditor and one of the worst correspondence letters we have read from the SEC suggest dismal accounting practices.” For more

Silicon Laboratories Inc.

Johnson Fistel Announces Investigation of Silicon Labs (SLAB) for Potential Securities Law Violations What is Johnson Fistel investigating? On January 29, 2024, Silicon Labs announced a one-week delay to its scheduled earnings conference call for the quarter ended on December 30, 2023. The company stated that it has identified a material weakness in internal control related to the operation and documentation of certain inventory controls as of December 30, 2023. The delay in reporting is intended to provide additional time to evaluate the impact of the material weakness on the company’s financial reporting as of the end of the quarterly period. Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471There is no cost or obligation to you What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under

10x Genomics, Inc.

Johnson Fistel Announces Investigation of 10x Genomics (TXG) for Potential Securities Law Violations Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations. Shareholders who have incurred losses on their investment in the company are encouraged to contact the firm to learn about potentially recovering their losses. For more details on the investigation, visit The investigation pertains to whether executives at the company misrepresented or failed to timely disclose material and adverse information to investors. What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619)

PTC Therapeutics, Inc.

PTCT ALERT: Johnson Fistel Encourages Investors to Inquire About PTC Therapeutics Securities Class Action Investigation. Shareholder rights law firm Johnson Fistel, LLP is investigating whether PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased PTC securities? If you purchased securities and suffered significant losses on your investment, join our investigation now: Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471 There is no cost or obligation to you. What is Johnson Fistel investigating? On September 15, 2023, PTC issued a press release “announc[ing] . . . that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on

BioNTech SE

BioNtech Class Action Update: Johnson Fistel Alerts Shareholders of Ongoing Legal Proceedings Class Period: March 30, 2022 and October 13, 2023 Lead Plaintiff Deadline: March 12, 2024 The class action against BioNTech includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) BioNTech overstated demand for and/or the commercial prospects of Comirnaty, the COVID-19 vaccine developed by the Company in collaboration with Pfizer ; (ii) the Company and/or Pfizer had accumulated excess inventory of raw materials for Comirnaty, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants that were produced at risk; (iii) accordingly, BioNTech was at an increased risk of recording significant inventory write-offs and other charges related to Comirnaty; and (iv) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. If you suffered a loss and are interested in learning more about being

M.D.C. Holdings, Inc.

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of M.D.C. Holdings, Inc. (NYSE: MDC) (“M.D.C.” or “the Company”) breached their fiduciary duties in connection with the proposed sale of the Company to Sekisuio House. On January 18, 2024, M.D.C. announced that it had entered a deal to merge with Sekisuio. Under the terms of the deal, M.D.C. shareholders will receive $63.00 per share in an all-cash offer. The investigation concerns whether the M.D.C. board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for M.D.C. shares of common stock. Nationally recognized, Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given analysts’ projections for future earnings and revenue growth. If you are a shareholder of M.D.C. and believe the proposed